PriceTargets.com logo

Jupiter Neurosciences - JUNS Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 1 Strong Buy Ratings
$1.22 As of 12/4/2025 01:00 AM ET
▲ +0.01 (0.83%)
Get New Jupiter Neurosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for JUNS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JUNS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Jupiter Neurosciences in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.22.

This chart shows the closing price for JUNS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 investment analysts is to moderate buy stock in Jupiter Neurosciences. This rating has held steady since September 2025, when it changed from a Strong Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/5/2025
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/24/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/17/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/11/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/5/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/28/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/22/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/14/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/19/2024Greenridge GlobalUpgradeStrong-Buy
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Jupiter Neurosciences logo
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.
Read More

Today's Range

Now: $1.22
Low: $1.19
High: $1.24

50 Day Range

MA: N/A

52 Week Range

Now: $1.22

Volume

30,208 shs

Average Volume

46,394 shs

Market Capitalization

$42.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Jupiter Neurosciences?

The following equities research analysts have issued stock ratings on Jupiter Neurosciences in the last year: Greenridge Global, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for JUNS.

What is the current price target for Jupiter Neurosciences?

0 Wall Street analysts have set twelve-month price targets for Jupiter Neurosciences in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Jupiter Neurosciences in the next year.
View the latest price targets for JUNS.

What is the current consensus analyst rating for Jupiter Neurosciences?

Jupiter Neurosciences currently has 1 sell rating and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for JUNS.

What other companies compete with Jupiter Neurosciences?

Other companies that are similar to Jupiter Neurosciences include China SXT Pharmaceuticals, Cassava Sciences, Incannex Healthcare, Surrozen and Unicycive Therapeutics. Learn More about companies similar to Jupiter Neurosciences.

How do I contact Jupiter Neurosciences' investor relations team?

Jupiter Neurosciences' physical mailing address is 1001 NORTH US HWY 1 SUITE 504, JUPITER FL, 33477. The company's listed phone number is 561 406 6154 and its investor relations email address is [email protected]. The official website for Jupiter Neurosciences is www.jupiterorphan.com. Learn More about contacing Jupiter Neurosciences investor relations.